ICON (NASDAQ: ICLR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
ICON Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ICON Company Info
The Company is a contract research organization, providing clinical research and development services on a global basis to the pharmaceutical, biotechnology and medical device industries.
News & Analysis
The company released its fourth-quarter earnings report, but that doesn't tell the whole story.
Find out how CROs profit from the biotech boom no matter what happens in the clinic.
Shares of the contract research organization soared more than 16% today. Is the move meaningful, or just market noise?
One Motley Fool analyst shares his top picks to own if Europe's bond buyback program ignites its economy.
Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.
Just the facts, Fool.
Checking expectations
Look here for a clue.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ICLR earnings call for the period ending September 30, 2021.
ICLR earnings call for the period ending June 30, 2021.
ICLR earnings call for the period ending March 31, 2021.
ICLR earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.